The mechanisms that orchestrate the functions of our bodies and keep us healthy are quite complex, involving critical molecular components that are still poorly understood. The journal Nature Communications has published ...
Oct 25, 2018
0
0
A combination of the immune checkpoint blocker, avelumab, plus the tyrosine kinase inhibitor (TKI), axitinib, significantly improves progression-free survival (PFS) in previously untreated patients with advanced renal cell ...
Oct 22, 2018
0
0
University of North Carolina Lineberger Comprehensive Cancer Center scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic change. Scientists have known this genetic change ...
Jul 19, 2018
0
65
Studying two rare inherited cancer syndromes, Yale Cancer Center (YCC) scientists have found the cancers are driven by a breakdown in how cells repair their DNA. The discovery, published today in Nature Genetics, suggests ...
Jul 16, 2018
0
43
The majority of patients eligible for cancer immunotherapy drugs known as checkpoint inhibitors received treatment within a few months of FDA approval, according to a new Yale-led study. The finding suggests that cancer immunotherapies ...
May 10, 2018
0
12
"You don't exactly want your tumour to take home and stick on your mantelpiece - give it to the research people and let them make some use of it."
Apr 13, 2018
0
5
Physicians who received payment from pharmaceutical companies for meals, talks and travel were more likely to prescribe those companies' drugs for two cancer types, a University of North Carolina Lineberger Comprehensive ...
Apr 9, 2018
0
1
Patients with an advanced form of kidney cancer had similar quality of life outcomes taking a drug called cabozantinib as those who received the standard treatment, everolimus, according to a new Northwestern Medicine study. ...
Feb 19, 2018
0
2
The Alliance for Clinical Trials in Oncology (the Alliance), in conjunction with industry partner Exelixis, today announced that the U.S. Food and Drug Administration (FDA) approved CABOMETYX (cabozantinib) tablets for the ...
Dec 20, 2017
0
4
A new study is believed to be the first to describe the unique role of androgens in kidney cancer, and it suggests that a new approach to treatment, targeting the androgen receptor (AR), is worth further investigation.
Oct 13, 2017
0
32
